TALVEY

all catalysts(0)

nothing on the calendar yet

News(8)

• Novartis wagers almost $8B on a Chinese biotech’s RNA drugs
  In exchange for a $575 million payment up front, Abogen Biosciences will furnish Novartis with access to its RNA technology, including an option to license its lead program ABO-2203.
  biopharma_dive · 2d ago
• GSK bags Chimagen’s trispecific T cell engager in deal worth up to $750M
  After inking a T cell engager pact with Chimagen Biosciences a few years ago, GSK is back for more, this time acquiring a multiple myeloma program from the antibody specialist.
  biospace · 19d ago
• GSK doubles down on Chimagen with $750M multiple myeloma wager
  GSK has bet up to $750 million on a Chimagen Biosciences trispecific T-cell engager, positioning the Big Pharma to start phase 1 development of the multiple myeloma drug candidate next year. The de…
  fiercebiotech · 19d ago
• Bristol Myers’ pivotal CAR-T multiple myeloma trial hits primary endpoint
  A pivotal trial of Bristol Myers Squibb’s GPRC5D-directed CAR-T cell therapy has hit its primary endpoint, furthering the drugmaker’s efforts to challenge Johnson & Johnson for the post-BCMA multip…
  fiercebiotech · 26d ago
• Legend Biotech CEO abruptly steps down without permanent replacement
  In a sudden leadership shift, Legend Biotech announced that its CEO, Ying Huang, Ph.D., resigned on Friday, with no permanent replacement yet named.
  fiercebiotech · 2mo ago
• Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma
  Novo is seeking an injunction that would halt allegedly “misleading” obesity drug ads. Elsewhere, the FDA began reviewing a highly anticipated medicine and a veteran investor landed at an AI startup.
  biopharma_dive · 2mo ago
• J&J multiple myeloma drug gains edge in earlier stage disease
  The latest results studying Talvey in combination with Darzalex Faspro support J&J’s efforts to expand the immunotherapy's use.
  biopharma_dive · 3mo ago
• Dr Silbermann on Clinical Trial Design Considerations in Multiple Myeloma
  Rebecca Silbermann, MD, MMS, outlines key trial design considerations in multiple myeloma, including supportive care measures and end point selection.
  onclive · 4mo ago